We validated the method according to the European Medicines Agency (EMA) guidance on bioanalytical method validation [12] and demonstrated its applicability to determine the drug's tumor distribution in skin tumor punch biopsies obtained from patients with CYLD mutations participating in the current Phase Ib/IIa clinical trial. The gene discussed is CYLD; the disease is skin neoplasm.